Surveillance and Follow-up In both studies, sufferers were followed for the intended treatment duration and noticed at fixed intervals that were similar for the rivaroxaban and comparison groups, at which time a checklist was used to elicit information on symptoms and signs of recurrent venous thromboembolism, bleeding, and adverse events. Patients had been instructed to report to the analysis center immediately if any of these events occurred. In instances of suspected venous thromboembolism, the protocol required objective testing. Result Assessments For both studies, the primary efficacy outcome was symptomatic, recurrent venous thromboembolism, defined as the composite of DVT or nonfatal or fatal pulmonary embolism, by using diagnostic criteria described previously12 .Frequent objective monitoring of irritation permits fine-tuning of the treatment of RA, leading to earlier remission, fewer inflammatory episodes and much less pain for sufferers, in the long term reducing functional loss and lowering health care costs and economic losses. We are very pleased that people succeeded in accomplishing this funding circular and we are self-confident that Akeso will achieve success in bringing its technology to advertise. We look forward to collaborating with the Akeso group to further advance it to medical use. We are excited about growing our portfolio with this promising medical technology firm. This financing round enables the team to build up the proposition towards the market and to clinical applications further, improving quality of life of RA sufferers..